HYBRIDGE is a global cross-industry community designed to bridge science, business, regulation, and innovation across the ecosystem of medicines developed from known molecules.
By bringing together experts, industry leaders, regulators, innovative technologies, and strategic partners, HYBRIDGE fosters collaboration and accelerates the development of differentiated medicines that address unmet needs, solve clinical challenges, and improve patient experience.
Through conferences, specialized training, and strategic initiatives, HYBRIDGE creates a dynamic environment for collaboration, knowledge exchange, and strategic discussion among professionals involved in hybrid medicines, 505(b)(2) products, and other innovation-driven approaches based on known molecules.
HYBRIDGE ANNUAL CONFERENCE
Innovation based on known molecules is becoming increasingly strategic, yet the pathway remains highly complex. Whether described as Value-Added Medicines, Hybrid Medicines, 505(b)(2) products, or other patient-centric approaches, success requires the alignment of regulatory requirements, clinical evidence, IP strategy, market access, and product differentiation from the earliest stages of development. In addition, significant differences exist not only between Europe and the US, but also across individual countries and healthcare systems, creating further challenges for global development strategies.
The HYBRIDGE Annual Conference is the first event dedicated to addressing these challenges through specialized training, real-world experience, expert discussions, and practical insights, while building bridges between regions, expertise, and industry perspectives. This first edition will focus on hybrid medicines in Europe and 505(b)(2) pathways in the US.
Organized by ANNION Consulting, HYBRIDGE is built around three core principles:
- Industry expertise
- An end-to-end strategic perspective
- A collaborative network of professionals shaping the future of innovation based on known molecules
